

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 June 2022 (02.06.2022)



(10) International Publication Number
WO 2022/111621 A1

(51) International Patent Classification:

C07D 239/48 (2006.01) A61P 35/00 (2006.01)
A61K 31/505 (2006.01)

(21) International Application Number:

PCT/CN2021/133429

(22) International Filing Date:

26 November 2021 (26.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2020/132454

27 November 2020 (27.11.2020) CN

PCT/CN2021/081236

17 March 2021 (17.03.2021) CN

(71) Applicant: **ANRUI BIOMEDICAL TECHNOLOGY (GUANGZHOU) CO., LTD.** [CN/CN]; Bldg. 2, Room 901, 188 Kaiyuan Avenue, Laidi Innovation Incubator, Huangpu District, Guangzhou, Guangdong 510530 (CN).

(72) Inventors: **CHENG, Dai**; Bldg. 2, Room 901, 188 Kaiyuan Avenue, Laidi Innovation Incubator, Huangpu District, Guangzhou, Guangdong 510530 (CN). **DING, Qiang**; Bldg. 2, Room 901, 188 Kaiyuan Avenue, Laidi Innovation Incubator, Huangpu District, Guangzhou, Guangdong 510530 (CN). **HE, Zhixiang**; Bldg. 2, Room 901, 188 Kaiyuan Avenue, Laidi Innovation Incubator, Huangpu District, Guangzhou, Guangdong 510530 (CN). **ZHOU, Xiaobo**; Bldg. 2, Room 901, 188 Kaiyuan Avenue, Laidi Innovation Incubator, Huangpu District, Guangzhou, Guangdong 510530 (CN). **ZHOU, Yang**; Bldg. 2, Room 901, 188 Kaiyuan Avenue, Laidi Innovation Incubator, Huangpu District, Guangzhou, Guangdong 510530 (CN). **YIN, Xiaohang**; Bldg. 2, Room 901, 188 Kaiyuan Avenue, Laidi Innovation Incubator, Huangpu District, Guangzhou, Guangdong 510530 (CN). **XIE, Zeqiang**; Bldg. 2, Room 901, 188 Kaiyuan Avenue, Laidi Innovation Incubator, Huangpu District, Guangzhou, Guangdong 510530 (CN).

(74) Agent: **SHANGHAI DIANSHI PARTNERS, P.C.**; JIANG, Fangwei/ZHANG, Cheng, Room 103, Bldg. 2, 608#, Shengxia Road, Pudong, Shanghai 201210 (CN).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

(54) Title: AMINOHETEROARYL KINASE INHIBITORS



Formula I



Formula II

(57) Abstract: Provided herein are novel compounds (e.g., Formula I or II), pharmaceutical compositions, and methods of using related to cyclin dependent kinases (CDKs). The compounds herein are typically CDK2 inhibitors, which can be used for treating a variety of diseases or disorders, such as cancer.



WO 2022/111621 A1